Oxcarbazepine-induced hyponatremia, a cross-sectional study.
In order to estimate the frequency of hyponatremia in patients treated with oxcarbazepine (OxCZ), a cross-sectional study was carried out. 21 of 41 patients being treated with the drug were found to be hyponatremic (serum sodium levels less than 135 mmol/l). None was found to be hypernatremic (serum sodium levels greater than 145 mmol/l). A non-significant trend towards increasing frequency of hyponatremia with increasing age was observed. Patients treated with dosages above 30 mg/kg/day had a significantly higher risk of becoming hyponatremic.